Literature DB >> 31520526

Pro-inflammatory role of high-mobility group box-1 on brain mast cells via the RAGE/NF-κB pathway.

Qing-Qing Qian1, Xiang Zhang2, Yi-Wei Wang1, Jia-Wen Xu1, Hong-Quan Dong1, Na-Na Li1, Yan-Ning Qian1, Bo Gui1.   

Abstract

High-mobility group box-1 (HMGB-1) acts as a pro-inflammatory cytokine contributing to the occurrence of many central inflammatory and infectious disorders. Brain mast cells (MCs) are the first responders to peripheral inflammatory stimulation because of their rapid response to external stimuli coupled with their release of preformed and newly synthesized reactive chemicals. Little is known about the involvement of brain MCs in the pro-inflammatory effects of HMGB-1 on the central nervous system (CNS). Thus, we investigated the activation process of MCs by HMGB-1 and explored whether this process is involved in the pro-inflammatory effects of HMGB-1 on the CNS. In this study, we used P815 cells to study the activating role of HMGB-1 on MCs and to explore its potential mechanism in vitro. In an in vivo study, adult male Sprague-Dawley rats received i.c.v. injection of sterile saline or cromoglycate (stabilizer of MCs) 30 min prior to i.p. injection of HMGB-1. Increased levels of tumor necrosis factor and IL-1β were observed in the P815 cells, as well as in the rats' brains, after HMGB-1 treatment. Pretreatment with the receptor of advanced glycation endproducts (RAGE)-siRNA inhibited the HMGB-1-induced inflammatory process in the P815 cells. Activation of the RAGE/nuclear factor-κB (NF-κB) pathway was observed in both the P815 cells and rats' brains. In addition, HMGB-1 induced the accumulation of brain MCs in the hippocampal CA1 region, and the blood-brain barrier was disrupted. Pretreatment with cromoglycate, a stabilizer of MCs, mitigated these HMGB-1-induced pro-inflammatory processes in rats. These findings indicate that brain MCs are involved in the pro-inflammatory effect of HMGB-1 on the CNS, probably via activating the RAGE/NF-κB pathway.
© 2019 International Society for Neurochemistry.

Entities:  

Keywords:  NF-κB; blood-brain barrier; high-mobility group box-1; mast cell; neuroinflammation; receptor of advanced glycation endproducts

Year:  2019        PMID: 31520526     DOI: 10.1111/jnc.14869

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  Plasma cytokine changes and its clinical significance in intracranial infection secondary to traumatic brain injury.

Authors:  Nannan Zhang; Zhibo Zhang; Hongxiao Wang; Dan Liu; Yingying Deng
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Inhibiting HMGB1-RAGE axis prevents pro-inflammatory macrophages/microglia polarization and affords neuroprotection after spinal cord injury.

Authors:  Hong Fan; Hai-Bin Tang; Zhe Chen; Hu-Qing Wang; Lei Zhang; Yu Jiang; Tao Li; Cai-Feng Yang; Xiao-Ya Wang; Xia Li; Sheng-Xi Wu; Gui-Lian Zhang
Journal:  J Neuroinflammation       Date:  2020-10-09       Impact factor: 8.322

3.  Electroacupuncture Ameliorates Tibial Fracture-Induced Cognitive Dysfunction by Elevating α7nAChR Expression and Suppressing Mast Cell Degranulation in the Hippocampus of Rats.

Authors:  Yudi Zhou; Cheng Hu; Chenlu Mao; Sha Li; Yaomei Cui; Yanning Qian
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-12       Impact factor: 2.650

Review 4.  Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing.

Authors:  Jason R Burchett; Jordan M Dailey; Sydney A Kee; Destiny T Pryor; Aditya Kotha; Roma A Kankaria; David B Straus; John J Ryan
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

Review 5.  Signal Transduction Pathways Activated by Innate Immunity in Mast Cells: Translating Sensing of Changes into Specific Responses.

Authors:  Zyanya P Espinosa-Riquer; Deisy Segura-Villalobos; Itzel G Ramírez-Moreno; Marian Jesabel Pérez Rodríguez; Mónica Lamas; Claudia Gonzalez-Espinosa
Journal:  Cells       Date:  2020-11-04       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.